Reverse Mergers and SPACs: Are APOs the New Norm for Biotechs Going Public?
2020 was an unprecedented year for Special Purpose Acquisition Corps (SPACs), an alternative public offering (APO) financing vehicle for listing on a public stock exchange. SPACs raised $82 billion, a figure greater than all previous years combined and representing nearly half of all capital raised in U.S. listed initial public offerings (IPOs). And the momentum continues to grow in 2021 as evidenced by 225 SPACs raising roughly $71 billion—a figure that accounts for more than 70% of all public stock sales and putting it on track to shatter last year’s record.
Watch the on-demand webinar where Scott Jordan leads a distinguished panel of experts in a discussion on the SPAC landscape from those immersed in the sector including sponsors, a leading attorney representing SPACs, and an investment banker facilitating concurrent financings.
In the on-demand webinar, panel members provide an overview of the financing structure, capital raised to date, case studies of closed transactions, and answers to the following questions:
Is my company a candidate for a SPAC?
Should my board evaluate SPACs as a viable alternative to an IPO?
How do I position my company to attract a SPAC and raise concurrent financing?
What are the advantages/disadvantages of going public via a SPAC, IPO, or Reverse Merger?
What are the key success factors for closing a SPAC and achieving post-close success?